Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo, M. J., Cardiel, M. J., Fraile, J. M., Mendez-Martinez, S., Martinez-Rincon, T., Subias, M., Polo, V., Ruberte, J., Ramirez, T., Vispe, E., Luna, C., Mayoral, J. A., Garcia-Martin, E.Year:
2020
Journal:
Biomaterials Science
DOI:
10.1039/d0bm01013h
File:
PDF, 1.90 MB
2020